The negative reason for drugs in the stock market; What to do a conversation with the manager The rapid rise in pharmaceutical stocks is entering a more moderate phase as the impact of the spring rate increases gradually fades. According to the manager of the Kian pharmaceutical sector fund, the continued growth beyond the market of this group is subject to the issuance of new price licenses in the coming months, and at the current stage symbols with potential for quantitative growth and active development plans will lead the performance of the industry.

The negative reason for drugs in the stock market; What to do a conversation with the manager The rapid rise in pharmaceutical stocks is entering a more moderate phase as the impact of the spring rate increases gradually fades. According to the manager of the Kian pharmaceutical sector fund, the continued growth beyond the market of this group is subject to the issuance of new price licenses in the coming months, and at the current stage symbols with potential for quantitative growth and active development plans will lead the performance of the industry.